Didronel

Didronel

 [di-dro´nel]
trademark for preparations of etidronate disodium, a bone calcium regulator.

etidronate disodium

Didronel, Didronel PMO (UK)

Pharmacologic class: Bisphosphonate

Therapeutic class: Bone resorption inhibitor, hypocalcemic agent

Pregnancy risk category B

Action

Blocks calcium absorption, slowing bone metabolism and reducing bone resorption and formation

Availability

Tablets: 200 mg, 400 mg

Indications and dosages

Paget's disease

Adults: 5 to 10 mg/kg P.O. daily as a single dose for up to 6 months, or 11 to 20 mg/kg P.O. daily for up to 3 months

Heterotopic ossification after hip replacement

Adults: 20 mg/kg P.O. daily for 1 month before and 3 months after surgery

Heterotopic ossification in spinal cord injury

Adults: Initially, 20 mg/kg P.O. daily for 2 weeks, decreased to 10 mg/kg P.O. daily for 10 weeks

Dosage adjustment

• Decreased glomerular filtration rate

Contraindications

• Hypersensitivity to drug or its components

• Abnormalities of esophagus, such as stricture or achalasia, that delay esophageal emptying

• Osteomalacia

Precautions

Use cautiously in:

• renal impairment, long bone fractures, active upper GI condition (such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers)

• pregnant or breastfeeding patients

• children (safety not established).

Administration

• Give with 6 to 8 oz of water 2 hours before first meal.

• Make sure patient doesn't eat for 2 hours after receiving dose.

• Know that therapy longer than 3 months is not recommended.

Adverse reactions

GI: nausea, constipation, stomatitis, diarrhea, esophageal irritation

Metabolic: hyperphosphatemia

Musculoskeletal: bone pain and tenderness, fractures, osteonecrosis of the jaw

Skin: rash

Interactions

Drug-drug. Warfarin: increased prothrombin time

Drug-diagnostic tests. Serum phosphorus: increased level

Patient monitoring

• Monitor fluid intake and output.

• Monitor patient for GI discomfort. Divide doses as needed to ease symptoms.

• Assess bowel pattern. If constipation occurs, increase fluids and administer stool softeners, as prescribed.

• Closely monitor renal function tests and serum phosphorus level.

Patient teaching

• Instruct patient to take drug first thing in morning on an empty stomach, with 6 to 8 oz of water only and to stay upright for at least 30 minutes afterward.

• Instruct patient not to take drug with food because of decreased drug absorption.

• Tell patient not to consume highcalcium products, such as milk or antacids, or vitamins and mineral supplements high in calcium, iron, magnesium, or aluminum, within 2 hours of taking dose.

Tell patient to immediately discontinue drug and notify prescriber if severe chest pain, difficulty or painful swallowing, or new or worsening heartburn occurs.

• Advise patient to report bone pain or decreased range of motion.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Didronel

(dĭ-drō′nəl)
A trademark for the drug etidronate disodium.

Didronel®

Etidronate, see there.

Didronel

A brand name for ETIDRONATE.
References in periodicals archive ?
Adrenolate (Fosomax), etidronate (Didronel) and zoledronic acid (Zometa) are the three most commonly-prescribed bisphosphonates.
In the search, we used the terms: (inflammatory bowel disease OR ulcerative colitis OR Crohn's disease) and (osteoporosis or osteopenia or (bone and (density or mass or loss))) and (exp Diphosphonates/or (bisphosphonate* or alendron* or fosamax or etidron* or didronel or risedron* or actonel or ibandron* or bonivaor zolendron* or zometa or zomera or aclasta or reclastor pamidron* or aredia)).
Table 1 First-Generation Drugs Second Generation Non-nitrogen containing BPs (NNBP) (Aminobisphosphonate Drugs) Nitrogen containing BPs (NBP) Bonefos (clodronate) Actonel (risedronate sodium) Relative potency of 10 PO and IV Relative potency of 5000 PO formulations Aredia (pamidronate disodium) Didronel (etidronate disodium) Relative potency 100 IV Relative potency of 1 PO Boniva (ibandronate sodium) Skelid (tiludronic disodium) Relative potency 10000 Relative potency of 10 PO PO and IV formulations Fosamax (alendronate sodium) Relative potency 1000 PO Reclast (zoledronic acid) Relative potency 100000 IV Formulation Infused annually for osteoporosis FDA approval pendin Zometa (zoledronic acid) Relative potency 100000 IV Table 2 Risk factors Literature Of Review 1.
Resection of heterotopic ossification and Didronel therapy-regaining wheelchair independence in the spinal cord injured patient.
"Bisphosphonate Medication (Fosamax, Actonel, Boniva, Aredia, Bonefos, Didronel or Zometa) (see Osteonecrosis of the Jaw)." The American Dental Association.
A recent case study reported dramatic improvements with etidronate (Didronel) 800 mg/ day for 3 months every 6 months, including softening of the caltom cinosis, reduced pain, and markedly increased joint mobility in a 26-year-old woman with severe calcinosis associated with dermatomyositis (J.
Bisphosphonates include Aclasta, Actonel, Aredia, Bondronat, Boniva, Didronel, Fosamax, Fosavance, Reclast, Skelid and Zometa.
Currently available bisphosphonates include alendronate (Fosamax), ibandronate (Boniva), risedronate (Actonel), etidronate (Didronel), pamidronate (Aredia), tiludronate (Skelid) and zoledronic acid (Reclast, Zometa).
Currently FDA-approved bisphosphonates, including Fosamax (alendronate), Actonel (risedronate), Didronel (etidronate), Boniva (ibandronate), and Reclast (Zometa) (zoledronate), are designed to strengthen bone by inhibiting normal osteoclastic bone resorbing activity, which slows the loss of bone mineral density (BMD), allowing the trabecular architecture to stabilize.
Primary Nitrogen Indication Containing Dose Etidronate (Didronel [R]) Paget's Disease No 300-750 mg Procter & Gamble daily for Pharmaceuticals 6 months Tiludronate (Skelid [R]) Paget's Disease No 400 mg daily Sanofi-aventis U.S.
In contrast, reports for 31 patients in Europe and Japan included a diagnosis of this cancer following: use of alendronate, risedronate (Actonel, Procter & Gamble), ibandronate (Boniva, Roche), and/or etidronate (Didronel, Procter & Gamble).
The bisphosphonate selected for administration was etidronate (Didronel) which has been shown to enhance bone structure and bone strength in overiectomized rats (Boyce et al., 1995; Katsumata et al., 1995).